RxDoctor Payments DataLook up a doctor →

Jeffery Degrauw, MD

Family Medicine · Layton, UTNPI 1780796441

Payments from drug & device makers

$920,696in general payments, 2019–2025

Across 994 payments — averaging $926.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$411K
  • Sanofi US Services Inc.$259K
  • Ironwood Pharmaceuticals, Inc$122K
  • AbbVie$48K
  • Akcea Therapeutics, Inc.$25K
  • Pfizer$20K
  • plus $35K from 54 others

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)45$410,988
Sanofi US Services Inc.259$259,441
Ironwood Pharmaceuticals, Inc10$122,049
AbbVie(2 entities)133$48,454
Akcea Therapeutics, Inc.78$24,717
Pfizer37$20,380
Gilead14$8,598
Madrigal Pharmaceuticals7$7,585
Novartis3$6,527
Sanofi Pasteur Inc.3$5,033
Eli Lilly3$1,139
Otsuka America Pharmaceutical, Inc.24$443
Lilly USA, LLC42$441
Boehringer Ingelheim22$424
Amarin Pharma, Inc.32$421
Astellas Pharma US Inc19$320
Amgen18$298
Johnson & Johnson18$263
GSK18$258
Takeda Pharmaceuticals U.S.A., Inc.23$236
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$230
Sunovion Pharmaceuticals Inc.23$229
Abbott18$217
Teva Pharmaceuticals USA, Inc.13$180
Sanofi-aventis U.S. LLC14$175
La Jolla Pharmaceutical Company1$126
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$118
Neurelis, Inc.7$101
Avanir Pharmaceuticals, Inc.6$93
Novo Nordisk5$69
Eisai Inc.5$68
E.r. Squibb & Sons, L.L.C.5$67
Sumitomo Pharma America, Inc.5$67
Biohaven Pharmaceutical Holding Company Ltd.3$63
Merck4$61
Nestle Healthcare Nutrition Inc.3$56
Axsome Therapeutics, Inc.3$52
Cranial Technologies, Inc3$50
Genentech USA, Inc.3$49
Alkermes, Inc.3$44
Biohaven Pharmaceuticals, Inc.3$42
Grifols USA, LLC2$41
Optinose US, Inc.2$38
Organon3$36
Shire North American Group Inc3$35
Lucid Diagnostics Inc.2$31
Lundbeck LLC2$31
Impel Pharmaceuticals Inc.2$31
Seqirus USA Inc2$26
Idorsia Pharmaceuticals US Inc2$26
Neurocrine Biosciences, Inc.1$23
Mylan Specialty L.p.1$21
GE HealthCare1$20
Xeris Pharmaceuticals, Inc.1$19
Vistapharm, Inc.1$18
Bolton Medical Inc1$17
Amneal Pharmaceuticals LLC1$16
Kowa Pharmaceuticals America, Inc.1$16
Jazz Pharmaceuticals Inc.1$16
Currax Pharmaceuticals LLC1$14

How this compares

$920,696 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah →

Medicare billing

Part B allowed, 2024
$105,876
Medicare patients
243
Services billed
1,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Layton

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →